Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Cited by (1,002)

Items 101–200 of 1,002

1. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy
   Harper Hubbeling, Emily A. Silverman, Laure Michaud, Ana Alarcón Tomás, Roni Shouval, Jessica R. Flynn, Sean M. Devlin, Neil Ari Wijetunga, Kathryn Ries Tringale, Connie Lee Batlevi et al. · 2022 · Transplantation and Cellular Therapy
2. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
   Syed Mahmood, Peter A. Riedell, Stephanie A. Feldman, Gina George, Stephen A Sansoterra, Thomas Althaus, Mahin Rehman, Elena Mead, Jennifer E. Liu, Richard B. Devereux et al. · 2023 · European Heart Journal
3. Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
   Kai Rejeski, David M. Cordas dos Santos, Nathan H. Parker, Veit Bücklein, Michael Winkelmann, Khushali S. Jhaveri, Lian Liu, Paul Trinkner, Sophie Günther, Philipp Karschnia et al. · 2023 · Cancer Immunology Research
4. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
   Jason R. Westin, Frederick Lundry Locke, Michael John Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David Bernard Miklos, Matthew L. Ulrickson, Miguel‐Angel Perales, Umar Farooq et al. · 2023 · Clinical Cancer Research
5. Follicular lymphoma: The long and winding road leading to your cure?
   Max J. Gordon, Mitchell Reed Smith, Loretta J. Nastoupil · 2022 · Blood Reviews
6. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
   Joanna C. Zurko, Imran A. Nizamuddin, Narendranath Epperla, Kevin A. David, Jonathon Brett Cohen, Tamara Kay Moyo, Thomas A. Ollila, Brian T. Hess, Ishan Roy, Robert Ferdman et al. · 2022 · Blood Advances
7. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
   Peter Dreger, Udo Holtick, Marion S. Subklewe, Bastian von Tresckow, Francis Ayuketang Ayuk, Eva Maria Wagner, Gerald Georg Wulf, Reinhardt Marks, Olaf Penack, Ulf Schnetzke et al. · 2022 · Bone Marrow Transplantation
8. Novel precision medicine approaches and treatment strategies in hematological malignancies
   Richard Rosenquist, Elsa Bernard, Tom Erkers, David W. Scott, Raphaël Itzykson, Philippe H. Rousselot, Jean Soulier, Martin Hutchings, Päivi Östling, Lucia B. Cavelier et al. · 2023 · Journal of Internal Medicine
9. CAR-T cell therapy for hematological malignancies: History, status and promise
   Chao Wang, Jianpeng Wang, Shusheng Che, Zhao Hai · 2023 · Heliyon
10. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
    Geoffrey Shouse, Andy J. Kaempf, Max J. Gordon, Andrew S. Artz, David Yashar, Audrey M. Sigmund, Gordon Smilnak, Steven Michael Bair, Agrima Mian, Lindsey A. Fitzgerald et al. · 2023 · Blood Advances
11. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
    Simone Filosto, Saran Vardhanabhuti, Miguel Ángel Canales, Xavier Poiré, Lazaros J. Lekakis, Sven de Vos, Craig Anthony Portell, Zixing Wang, Christina To, Marco Schupp et al. · 2023 · Blood Cancer Discovery
12. Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis
    Min Woo Han, So Yeong Jeong, Chong Hyun Suh, Hyesun Park, Jeffrey P. Guenette, Raymond Y. Huang, Kyung Won Kim, Dok Hyun Yoon · 2024 · Frontiers in Neurology
13. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
    Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee · 2022 · JAMA Network Open
14. CAR T‐cell therapy in large B cell lymphoma
    Alexander P. Boardman, Gilles Salles · 2023 · Hematological Oncology
15. 2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
    Montreh Tavakkoli, Stefan Klaus Barta · 2023 · American Journal of Hematology
16. Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
    T. Bock, Chanukya K Colonne, S. Fiorenza, C. Turtle · 2025 · Nature Reviews Clinical Oncology
17. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma
    Katharine Louise Lewis, Lasse Hjort Jakobsen, Diego R. Villa, Karin Ekstrom Ekstroem Smedby, Kerry J. J. Savage, Toby Andrew Eyre, Kate Cwynarski, Mark J. Bishton, Christopher Paul Fox, Eliza Anne Hawkes et al. · 2023 · Journal of Clinical Oncology
18. Recognizing, defining, and managing CAR-T hematologic toxicities
    Kai Rejeski, Marion S. Subklewe, Frederick Lundry Locke · 2023 · Hematology
19. Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
    Jing Zhang, Yan Gu, Baoan Chen · 2023 · Cancer Management and Research
20. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
    Clara Beatriz García-Calderón, Belén Sierro-Martínez, Estefanía García‐Guerrero, Luzalba Sanoja-Flores, Raquel Muñoz-García, Victoria Ruiz-Maldonado, María Reyes Jiménez‐León, Javier Delgado‐Serrano, Águeda Molinos-Quintana, Beatriz Guijarro-Albaladejo et al. · 2023 · Frontiers in Immunology
21. Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report
    Lingshuang Sheng, Yilun Zhang, Qi Song, Xufeng Jiang, Weiguo Cao, Lei Li, Hongmei Yi, Xiangqin Weng, Sheng Chen, Zhongmin Wang et al. · 2023 · Frontiers in Immunology
22. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
    Adam S. Kittai, David Alan Bond, Ying Huang, Seema Ali Bhat, Emily Blyth, John C. Byrd, Julio C. Chávez, Matthew Steven Davids, Jamie P Dela Cruz, Mark R. Dowling et al. · 2024 · Journal of Clinical Oncology
23. Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
    Patrick Derigs, Maria‐Luisa Schubert, Peter Dreger, Anita Schmitt, Schayan Yousefian, Simon F. Haas, Caroline Röthemeier, Brigitte Neuber, Angela Hückelhoven‐Krauss, Monika Brüggemann et al. · 2024 · Leukemia
24. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
    Nancy L. Bartlett, Uwe Hahn, Won Seog Kim, Isabelle Fleury, Kamel Laribi, Juan Bergua, Krimo K. Bouabdallah, Nicholas Allen Forward, Fontanet Delices Bijou, David A. Macdonald et al. · 2025 · Journal of Clinical Oncology
25. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
    Frederick Lundry Locke, Javier L Munoz, Michael Timothy Tees, Lazaros J. Lekakis, Sven de Vos, R. Nath, Don Ambrose Stevens, Shahbaz Ali Malik, Geoffrey Shouse, Mehdi Hamadani et al. · 2025 · Journal of Clinical Oncology
26. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
    Aiman J. Faruqi, John A. Ligon, Paul Borgman, Seth M. Steinberg, Toni Foley, Lauren Little, Crystal Lee Mackall, Daniel W. Lee, Terry J. Fry, Haneen Shalabi et al. · 2022 · Blood Advances
27. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis
    Gülçin Telli Dizman, José María Aguado, Mario Fernández‐Ruiz · 2022 · Expert Review of Anti-infective Therapy
28. Mechanisms and management of CAR T toxicity
    Christopher James Ferreri, Manisha Bhutani · 2024 · Frontiers in Oncology
29. Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma
    Zi‐Xun Yan, Yan Dong, Niu Qiao, Yilun Zhang, Wen Wu, Yue Zhu, Li Wang, Shu Cheng, Peng-Peng Xu, Zisong Zhou et al. · 2024 · Nature Communications
30. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
    Manali Kirtikumar Kamdar, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim G. N. J. Mutsaers, Francisco J. Hernandez‐Ilizaliturri et al. · 2025 · Journal of Clinical Oncology
31. Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients
    Sara Harrysson, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Tarec Christoffer El‐Galaly, Birgitta Sander, Kristina Sonnevi, Per‐Ola Andersson, Mats Jerkeman, Karin Ekstrom Ekstroem Smedby · 2022 · British Journal of Haematology
32. Sex hormones, the anticancer immune response, and therapeutic opportunities
    Fabio Conforti, Laura Pala, Diletta Di Mitri, Chiara Catania, Emilia Cocorocchio, Daniele Laszlo, Giovanni Luca Ceresoli, Marzia Locatelli, Flaminia Facella, Tommaso Martino De Pas et al. · 2025 · Cancer Cell
33. Complex neural-immune interactions shape glioma immunotherapy
    Kun-Wei Song, Michael K. Lim, Michelle Monje · 2025 · Immunity
34. Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy
    Ester Márquez‐Algaba, Gloria Iacoboni, Berta Pernas, Juliana Esperalba, Ibai Los Arcos, Vı́ctor Navarro, Arnau Monforte, Francisco Beas, Adaia Albasanz‐Puig, Cecilia del Carmen Carpio et al. · 2022 · Transplantation and Cellular Therapy
35. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
    H. Balke-Want, V. Keerthi, N. Gkitsas, A. Mancini, G. Kurgan, C. Fowler, Peng Xu, Xi-Kun Liu, K. Asano, Sunny Patel et al. · 2023 · Molecular Cancer
36. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells
    Paolo Strati, Xubin Li, Qing Deng, Mario Luiz Marques-Piubelli, Jared M. Henderson, Grace Watson, Laurel Deaton, Taylor Cain, Haopeng Yang, Vida Ravanmehr et al. · 2023 · Cell Reports Medicine
37. Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
    Gloria Iacoboni, Josu Iraola‐Truchuelo, Maeve A O'Reilly, Vı́ctor Navarro, Tobias Menne, Mi Kwon, Ana África Martín‐López, Sridhar Chaganti, Javier Delgado, Claire Roddie et al. · 2024 · HemaSphere
38. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
    Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali Kirtikumar Kamdar, Bradley M. Haverkos, James K. Godfrey, Melissa A. Babcook et al. · 2023 · Blood Advances
39. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma
    Narendranath Epperla, Ambuj Kumar, Syed Ali Abutalib, Farrukh Tauseef Awan, Yi‐Bin Chen, Ajay K. Gopal, Jennifer Holter Chakrabarty, Natasha K. Kekre, Catherine J. Lee, Lazaros J. Lekakis et al. · 2023 · Transplantation and Cellular Therapy
40. Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
    Jessica S Little, Megha Tandon, Joseph Hong, Omar Nadeem, Adam Samuel Sperling, Noopur S Raje, Nikhil C. Munshi, Matthew J. Frigault, Sara Barmettler, Sarah Page Hammond · 2023 · Blood Advances
41. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy
    Abraham Sebastian Kanate, Navneet S. Majhail, Zachariah Michael DeFilipp, Binod Dhakal, Bhagirathbhai Dholaria, Betty K. Hamilton, Alex Francisco Herrera, Yoshihiro Inamoto, Tania Jain, Miguel‐Angel Perales et al. · 2023 · Transplantation and Cellular Therapy
42. Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
    Iman Abou Dalle, Rémy Duléry, Nour M. Moukalled, Laure Ricard, Nicolas Stocker, Jean El Cheikh, Mohamad Mohty, Ali A. Bazarbachi · 2024 · Blood Cancer Journal
43. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
    Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm‐Kuczera, Vladan Vučinić, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher et al. · 2025 · Blood Advances
44. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Jee H. Choe, Hisham Abdel‐Azim, William V. Padula, Mohamed Abou‐El‐Enein · 2022 · JAMA Network Open
45. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
    Dilara Akhoundova, Katja Seipel, Ulrike Bacher, Marie-Noëlle Kronig, Naomi Azur Porret, Gertrud Wiedemann, Michael Daskalakis, Thomas Pabst · 2023 · BMC Cancer
46. The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention
    Jessica S Little, Eleftheria Kampouri, Daniel Z. P. Friedman, Todd P McCarty, George R. Thompson, Dimitrios P. Kontoyiannis, José A. Vázquez, John W. Baddley, Sarah Page Hammond · 2024 · Open Forum Infectious Diseases
47. Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
    Guillaume Cartron, Roch Houot, Yassine Al Tabaa, Fabien Le Bras, Loïc Ysebaert, Sylvain Choquet, Fabrice Jardin, Jacques‐Olivier Bay, François‐Xavier Gros, Franck Morschhauser et al. · 2025 · Nature Cancer
48. Optimizing CAR T cell therapy for solid tumours: a clinical perspective
    Jiarui Li, Chang Liu, Panpan Zhang, Lin Shen, Changsong Qi · 2025 · Nature Reviews Clinical Oncology
49. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
    Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John G. Kuruvilla, David Cunningham, Justin Paul Kline, Nathalie A. Johnson, Neha Mehta–Shah et al. · 2023 · Blood Advances
50. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
    Chieh Yang, John Nguyen, Yun Yen · 2023 · Journal of Biomedical Science
51. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update
    Mathieu Bellal, Jolan Malherbe, Gandhi Laurent Damaj, Damien du Cheyron · 2024 · Critical Care
52. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations
    Philipp Blüm, Sabine Käyser · 2024 · Cancers
53. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
    Pierre Sesques, Amy A. Kirkwood, Mi Kwon, Kai Rejeski, Michael David Jain, Roberta Di Blasi, Gabriel Brisou, François‐Xavier Gros, Fabien Le Bras, Pierre Bories et al. · 2024 · Journal of Hematology & Oncology
54. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review
    Lakshmi Prasanna Vaishnavi Kattamuri, Bhavesh Mohan Lal, Nikhil Vojjala, Mansi Jain, Kunal Sharma, Siddharth Jain, Samer Al Hadidi · 2025 · Rheumatology International
55. Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
    Allison Marie Bock, Narendranath Epperla · 2025 · Journal of Hematology & Oncology
56. DLBCL 1L—What to Expect beyond R-CHOP?
    Maike Stegemann, Sophy Denker, Clemens A. Schmitt · 2022 · Cancers
57. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
    Yuan Xia, Jue Zhang, Jing Li, Lina Zhang, Jianyong Li, Lei Fan, Lijuan Chen · 2022 · Annals of Medicine
58. Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
    Fabian Frontzek, Imke E. Karsten, Norbert Schmitz, Georg Lenz · 2022 · Therapeutic Advances in Hematology
59. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
    Nathan Fergusson, Komal Adeel, Natasha K. Kekre, Harold L. Atkins, Kevin Anthony Hay · 2023 · Frontiers in Immunology
60. Challenges and strategies associated with CAR-T cell therapy in blood malignancies
    Zhaoyun Liu, Wenhui Lei, Hao Wang, Xiaohan Liu, Rong Fu · 2024 · Experimental Hematology and Oncology
61. Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
    Philipp Berning, Evgenii Shumilov, Markus Maulhardt, Hristo Boyadzhiev, Andrea Kerkhoff, Simon Call, Christian Reicherts, Anna Ossami Saidy, Enver Aydilek, Michèle Hoffmann et al. · 2024 · HemaSphere
62. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
    Nausheen Ahmed, William Wesson, Forat Umair Lutfi, David L. Porter, Veronika Bachanová, Loretta J. Nastoupil, Miguel‐Angel Perales, Richard Thomas Maziarz, Jamie Brower, Gunjan L. Shah et al. · 2024 · Blood Advances
63. Gut Microbiota Modulation through Akkermansia spp . Supplementation Increases CAR T-cell Potency
    Laura Marcos-Kovandzic, Michele Avagliano, Myriam Ben Khelil, Janesa Srikanthan, Rim Abdallah, Valentina Petrocelli, Jessica Rengassamy, Alexia Alfaro, Mathilde Bied, Marine Fidelle et al. · 2025 · Cancer Discovery
64. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
    Frederick Lundry Locke, Sattva Swarup Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, Caron Alyce Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman et al. · 2024 · Transplantation and Cellular Therapy
65. Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity
    Taisuke Kondo, François X. P. Bourassa, Sooraj R. Achar, Justyn DuSold, Pablo F. Céspedes, Makoto Ando, Alka Dwivedi, Josquin Moraly, Christopher Daniel Chien, Saliha Majdoul et al. · 2025 · Cell
66. Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
    Catherine Thiéblemont, María Gomes da Silva, Sirpa Leppä, Georg Lenz, Anne‐Ségolène Cottereau, Christopher Paul Fox, Armando López‐Guillermo, Tim Illidge, Wojciech J. Jurczak, Hans Theodor Eich et al. · 2025 · HemaSphere
67. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
    Miguel‐Angel Perales, Larry Don Anderson, Tania Jain, Saad S. Kenderian, Olalekan O. Oluwole, Gunjan L. Shah, Jakub Svoboda, Mehdi Hamadani · 2022 · Transplantation and Cellular Therapy
68. Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis
    Liat Shargian, Pia Raanani, Moshe Yeshurun, Anat Gafter‐Gvili, Ronit Gurion · 2022 · British Journal of Haematology
69. The potential and promise for clinical application of adoptive T cell therapy in cancer
    Yinqi Li, Yeteng Zheng, Taiqing Liu, Chuanyun Liao, Guobo Shen, Zhiyao He · 2024 · Journal of Translational Medicine
70. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
    Andrew Looka, David Augustus Qualls, Daniel Matthews, Robert Allyn Redd, Christopher G. Sakellis, Caitlyn Duffy, Jamie Dela Cruz, Anna Saucier, Philippe A. Armand, Jennifer Leigh Crombie et al. · 2024 · Blood Advances
71. Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
    Evgenii Shumilov, Rebecca Wurm‐Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp Bernhard Staber, Paolo Mazzeo, Corinna Leng et al. · 2024 · Blood Advances
72. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
    Frederick Lundry Locke, Tanya Siddiqi, Caron Alyce Jacobson, Sarah Nikiforow, Sairah Ahmed, David Bernard Miklos, Yi Lin, Matthew Alexander Lunning, Brian Thomas Hill, Armin Ghobadi et al. · 2025 · Blood Advances
73. Engineering live cell surfaces with polyphenol-functionalized nanoarchitectures
    Yunxiang He, Qinling Liu, Yuanmeng He, Siqi Deng, Junling Guo · 2025 · Chemical Science
74. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma
    Marta Canelo‐Vilaseca, Mohamad Sabbah, Roberta Di Blasi, Caterina Cristinelli, Anna Maria Sureda, Sophie Caillat‐Zucman, Catherine Thiéblemont · 2025 · Bone Marrow Transplantation
75. Large B cell lymphoma microenvironment archetype profiles
    Xubin Li, Kartik Singhal, Qing Deng, Dai Chihara, David A. Russler‐Germain, Robert Andrew Harkins, Jared M. Henderson, Kotaro Arita, Atish Kizhakeyil, Ryan Sun et al. · 2025 · Cancer Cell
76. Tracing the development of CAR-T cell design: from concept to next-generation platforms
    Ahdab Alsaieedi, Kawther A. Zaher · 2025 · Frontiers in Immunology
77. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
    Miguel‐Angel Perales, John G. Kuruvilla, Julia Thornton Snider, Sachin Vadgama, Rob S. Blissett, Fadoua El Moustaid, Nathaniel Smith, Anik R. Patel, Patrick B. Johnston · 2022 · Transplantation and Cellular Therapy
78. Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis
    Gemma K. Reynolds, Beatrice Sim, Tim D. Spelman, Ashmitha Thomas, Anthony Longhitano, Mary Ann Anderson, Karin Thursky, Monica A. Slavin, Benjamin W. Teh · 2023 · Critical Reviews in Oncology/Hematology
79. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
    Pınar Ataca Atilla, Erden Atilla · 2022 · Translational Oncology
80. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
    Veit Bücklein, Ariel Perez Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinović, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann et al. · 2023 · HemaSphere
81. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
    Annalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, Alice Di Rocco, Silva Ljevar, Martina Magni, Piera Angelillo, Anna Maria Barbui, Ilaria Cutini, Anna Dodero et al. · 2024 · Leukemia
82. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
    Matthew J. Frigault, Charlotte Graham, Trisha R. Berger, Julie Ritchey, Nora Horick, Areej R El-Jawahri, Irene Scarfò, Andrea Schmidts, Nicholas J. Haradhvala, Marc Wehrli et al. · 2024 · Blood
83. Noncanonical and mortality-defining toxicities of CAR T cell therapy
    Kai Rejeski, Joshua Aiden Hill, Saurabh Dahiya, Michael David Jain · 2025 · Nature Medicine
84. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
    Barbara Mandriani, Eleonora Pellè, Francesco Mannavola, Antonio J. Palazzo, Renè Massimiliano Marsano, Giuseppe Ingravallo, Gerardo Cazzato, Maria Cecilia Ramello, Camillo Porta, Jonathan Strosberg et al. · 2022 · Journal for ImmunoTherapy of Cancer
85. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma
    Abi Vijenthira, John G. Kuruvilla, Michael Crump, Michael David Jain, Anca A. Prica · 2022 · Journal of Clinical Oncology
86. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
    Kai Rejeski, Zhijie Wu, Viktoria Blumenberg, Wolfgang Gerhard Kunz, Susanna M. Müller, Sachiko Kajigaya, Shouguo Gao, Veit Bücklein, Lisa Frölich, Christian Schmidt et al. · 2022 · Blood
87. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
    Adam S. Zayac, Daniel Jeffrey Landsburg, Mitchell E. Hughes, Allison Marie Bock, Grzegorz S. Nowakowski, Emily C. Ayers, Mark Girton, Marie Hu, Amy K. Beckman, Shaoying Li et al. · 2023 · Blood Advances
88. Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities
    Matthew Ho, Saurabh Zanwar, Jonas Paludo · 2023 · European Journal Of Haematology
89. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy
    Yifan Zhao, Xiaomei Zhang, Meng Zhang, Ruiting Guo, Yi Zhang, Yedi Pu, Haibo Zhu, Pengjiang Liu, Yu Zhang, Xiaoyuan He et al. · 2024 · Annals of Hematology
90. Defining primary refractory large B-cell lymphoma
    Allison Marie Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew John Maurer, Amy A. Ayers, Brad S. Kahl, Peter Martin, Jonathon Brett Cohen, Carla Casulo et al. · 2024 · Blood Advances
91. ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma
    Mireia Bachiller, Nina Barceló-Genestar, Alba Rodríguez-García, Letícia Alserawan, Cèlia Dobaño‐López, Marta Giménez-Alejandre, Joan Castellsagué, Salut Colell, Marc Otero-Mateo, Asier Antoñana-Vildosola et al. · 2024 · Molecular Therapy
92. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis
    Peter A. Riedell, Connor B. Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard Thomas Maziarz, Marie Hu, Jamie Brower, Wei‐Ting Hwang, Stephen J. Schuster et al. · 2024 · Blood Advances
93. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
    Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew Genyeh Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine M. Zain et al. · 2022 · Blood
94. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss
    Fateeha Furqan, Nirav Niranjan Shah · 2022 · Annual Review of Medicine
95. Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity
    Tyler Fugere, Alan Baltz, Akash Mukherjee, Mamatha Gaddam, Ankur Varma, Muthu Kumaran Veeraputhiran, Cesar Gentille Sanchez · 2023 · Cancers
96. Advances and prospects of mRNA vaccines in cancer immunotherapy
    Yixuan Liu, Qijia Yan, Zhaoyang Zeng, Chunmei Fan, Wei Xiong · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
97. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas
    J. Erika Haydu, Jeremy S. Abramson · 2024 · Blood Advances
98. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy
    Hazim Ababneh, Jeremy S. Abramson, Patrick Connor Johnson, Chirayu G. Patel · 2022 · Radiotherapy and Oncology
99. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
    Anthony C. Wood, Ariel Perez Perez, Brian Arciola, Kedar Patel, Grace Johnson, Elizabeth C. DiMaggio, Christina A. Bachmeier, Kayla M. Reid, Salvatore A. Corallo, Melanie Hidalgo Vargas et al. · 2022 · Transplantation and Cellular Therapy
100. Advances in landscape and related therapeutic targets of the prostate tumor microenvironment
     Duocai Li, Weidong Xu, Yifan Emily Chang, Yu‐Tian Xiao, Yundong He, Shancheng Ren · 2023 · Acta Biochimica et Biophysica Sinica